Stockscreener 앱 받기
1.77
1.12%
-0.02
InspireMD Inc. 주식(NSPR)의 최신 뉴스
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading - MSN
Geopolitics Watch: Can InspireMD Inc keep up with sector leadersMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
InspireMD Q2 2025 Earnings Preview - MSN
InspireMD targets $13M–$15M in 2026 revenue as CGuard Prime gains US traction - MSN
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
InspireMD, Inc. (NSPR) reports Q4 loss, beats revenue estimates - MSN
InspireMD revenue up 62% to USD 3.1M in Q4 2025 - Medical Buyer
Returns Recap: Can InspireMD Inc outperform in the next rallyDay Trade & Safe Entry Trade Reports - baoquankhu1.vn
InspireMD’s Growth Hinges on Real CAS Market Size and Physician Adoption - TipRanks
InspireMD Reports 62% Q4 Revenue Growth and Sets 2026 Outlook for CGuard Prime Carotid Stent System - Minichart
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats By Investing.com - Investing.com South Africa
InspireMD earnings beat by $0.05, revenue topped estimates - Investing.com Canada
InspireMD, Inc. (NSPR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats - Investing.com
InspireMD, Inc. Overview: CGuard Carotid Stent Technology, Business Strategy, and Market Leadership in Stroke Prevention 72 - Minichart
InspireMD Reports Strong Q4 2025 Growth and Expansion - TipRanks
FDA PMA and global expansion reshape InspireMD (NSPR) carotid focus - Stock Titan
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
InspireMD Q4 net income USD -11.761 million - marketscreener.com
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
INSPIREMD ($NSPR) Releases Q4 2025 Earnings - Quiver Quantitative
InspireMD (NSPR) revenue climbs 28% in 2025 as net loss widens - Stock Titan
InspireMD Q4 revenue rises 62%, beats estimates - TradingView
NSPR: Q4 2025 revenue surged 62% year-over-year, with 2026 revenue growth projected at up to 65% - TradingView
Stroke stent maker InspireMD lifts sales 62% and targets up to $15M in 2026 - Stock Titan
InspireMD Q4 2025 earnings preview - MSN
InspireMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
921,587 Shares in InspireMD, Inc. $NSPR Purchased by Ghisallo Capital Management LLC - MarketBeat
Stock Recap: Is InspireMD Inc a momentum stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Rosalind Advisors Inc. Purchases 1,616,644 Shares of InspireMD, Inc. $NSPR - MarketBeat
InspireMD (NSPR) price target increased by 25.00% to 5.10 - MSN
Aug Opening: Can InspireMD Inc outperform in the next rally2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
Aug PreEarnings: Is InspireMD Inc stock risky to hold now2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
InspireMD, Inc. Scheduled to Release Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Carotid stent developer InspireMD sets March 18 results call - Stock Titan
InspireMD (NSPR) price target decreased by 11.11% to 4.08 - MSN
Is InspireMD Inc. stock dividend yield sustainableWeekly Risk Report & Verified Momentum Watchlists - Naître et grandir
InspireMD Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
InspireMD announces dismissal of chief operating officer Andrea Tommasoli By Investing.com - Investing.com Australia
InspireMD Announces Planned Departure of Chief Operating Officer - TipRanks
InspireMD announces dismissal of chief operating officer Andrea Tommasoli - Investing.com
Embolic Protection Devices Market to Reach USD 1,161.31 Million by 2032, Growing at a CAGR of 7.58% | DelveInsight - Barchart.com
InspireMD dismisses COO Andrea Tommasoli; last day expected Sept 1, 2026 - TradingView
InspireMD (NSPR) outlines COO dismissal, French-law notice and €61k severance - Stock Titan
InspireMD, Inc. Announces Dismissal of Chief Operating Officer Andrea Tommasoli, Effective April 1, 2026 - marketscreener.com
Tangible book value per share of InspireMD Inc. – LSX:A3CMP3 - TradingView
NSPR Technical Analysis & ETF Price Forecast - Intellectia AI
Can InspireMD Inc. outperform in the next rallyJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - mfd.ru
NSPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stock Report: Why is InspireMD Inc stock going upEarnings Growth Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
InspireMD (NSPR) Price Target Increased by 25.00% to 5.10 - Nasdaq
Lake Street reiterates InspireMD stock rating citing market growth By Investing.com - Investing.com Canada
Director adds 2,710 InspireMD (NSPR) shares in amended Form 4 - Stock Titan
What hedge fund activity signals for InspireMD Inc. stock2025 Growth vs Value & Detailed Earnings Play Strategies - mfd.ru
1.53%
자본화:
|
볼륨(24시간):